These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 31670958)

  • 1. C1-CBP-vancomycin: Impact of a Vancomycin C-Terminus Trimethylammonium Cation on Pharmacological Properties and Insights into Its Newly Introduced Mechanism of Action.
    Wu ZC; Isley NA; Okano A; Weiss WJ; Boger DL
    J Org Chem; 2020 Feb; 85(3):1365-1375. PubMed ID: 31670958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maxamycins: Durable Antibiotics Derived by Rational Redesign of Vancomycin.
    Wu ZC; Boger DL
    Acc Chem Res; 2020 Nov; 53(11):2587-2599. PubMed ID: 33138354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vancomycin C-Terminus Guanidine Modifications and Further Insights into an Added Mechanism of Action Imparted by a Peripheral Structural Modification.
    Wu ZC; Cameron MD; Boger DL
    ACS Infect Dis; 2020 Aug; 6(8):2169-2180. PubMed ID: 32598127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peripheral modifications of [Ψ[CH
    Okano A; Isley NA; Boger DL
    Proc Natl Acad Sci U S A; 2017 Jun; 114(26):E5052-E5061. PubMed ID: 28559345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. N-Terminus Alkylation of Vancomycin: Ligand Binding Affinity, Antimicrobial Activity, and Site-Specific Nature of Quaternary Trimethylammonium Salt Modification.
    Wu ZC; Isley NA; Boger DL
    ACS Infect Dis; 2018 Oct; 4(10):1468-1474. PubMed ID: 30067012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antagonistic Effect of Colistin on Vancomycin Activity against Methicillin-Resistant Staphylococcus aureus in
    Choi S; Moon SM; Park SJ; Lee SC; Jung KH; Sung HS; Kim MN; Jung J; Kim MJ; Kim SH; Lee SO; Choi SH; Jeong JY; Woo JH; Kim YS; Chong YP
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32041713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emergence of vancomycin-intermediate and -resistant Staphylococcus aureus among methicillin-resistant S. aureus isolated from clinical specimens in the northwest of Iran.
    Ghahremani M; Jazani NH; Sharifi Y
    J Glob Antimicrob Resist; 2018 Sep; 14():4-9. PubMed ID: 29454049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Killing Mechanism of Teixobactin against Methicillin-Resistant Staphylococcus aureus: an Untargeted Metabolomics Study.
    Hussein M; Karas JA; Schneider-Futschik EK; Chen F; Swarbrick J; Paulin OKA; Hoyer D; Baker M; Zhu Y; Li J; Velkov T
    mSystems; 2020 May; 5(3):. PubMed ID: 32457238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chlorobiphenyl-desleucyl-vancomycin inhibits the transglycosylation process required for peptidoglycan synthesis in bacteria in the absence of dipeptide binding.
    Goldman RC; Baizman ER; Longley CB; Branstrom AA
    FEMS Microbiol Lett; 2000 Feb; 183(2):209-14. PubMed ID: 10675585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of growth phase and pH on the in vitro activity of a new glycopeptide, oritavancin (LY333328), against Staphylococcus aureus and Enterococcus faecium.
    Mercier RC; Stumpo C; Rybak MJ
    J Antimicrob Chemother; 2002 Jul; 50(1):19-24. PubMed ID: 12096002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activities of quinupristin-dalfopristin and cefepime, alone and in combination with various antimicrobials, against multidrug-resistant staphylococci and enterococci in an in vitro pharmacodynamic model.
    Allen GP; Cha R; Rybak MJ
    Antimicrob Agents Chemother; 2002 Aug; 46(8):2606-12. PubMed ID: 12121940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protective activity of anti-lipoteichoic acid monoclonal antibody in single or combination therapies in methicillin-resistant Staphylococcus aureus-induced murine sepsis models.
    Ohsawa H; Baba T; Enami J; Hiramatsu K
    J Infect Chemother; 2020 May; 26(5):520-522. PubMed ID: 32001173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vancomycin-loaded nanoparticles against vancomycin intermediate and methicillin resistant Staphylococcus aureus strains.
    Simon A; Moreira MLA; Costa IFJB; de Sousa VP; Rodrigues CR; da Rocha E Lima LMT; Sisnande T; do Carmo FA; Leal ICR; Dos Santos KRN; da Silva LCRP; Cabral LM
    Nanotechnology; 2020 Sep; 31(37):375101. PubMed ID: 32470951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of cefazolin co-administration with vancomycin to reduce development of vancomycin-intermediate Staphylococcus aureus.
    Singh NB; Yim J; Jahanbakhsh S; Sakoulas G; Rybak MJ
    Diagn Microbiol Infect Dis; 2018 Aug; 91(4):363-370. PubMed ID: 29807674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emergence of vancomycin-resistant Staphylococcus aureus identified in the Tlemcen university hospital (North-West Algeria).
    Rebiahi SA; Abdelouahid DE; Rahmoun M; Abdelali S; Azzaoui H
    Med Mal Infect; 2011 Dec; 41(12):646-51. PubMed ID: 22033230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multidrug and vancomycin resistance among clinical isolates of
    Olufunmiso O; Tolulope I; Roger C
    Afr Health Sci; 2017 Sep; 17(3):797-807. PubMed ID: 29085408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Purified citritin in combination with vancomycin inhibits VRE in vitro and in vivo.
    Oliveira KS; Martins Queiroz PR; Marques Fensterseifer IC; Migliolo L; Oliveira AL; Franco OL
    Microbiology (Reading); 2017 Nov; 163(11):1525-1531. PubMed ID: 29043959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ceftaroline pharmacodynamic activity versus community-associated and healthcare-associated methicillin-resistant Staphylococcus aureus, heteroresistant vancomycin-intermediate S. aureus, vancomycin-intermediate S. aureus and vancomycin-resistant S. aureus using an in vitro model.
    Zhanel GG; Rossnagel E; Nichol K; Cox L; Karlowsky JA; Zelenitsky S; Noreddin AM; Hoban DJ
    J Antimicrob Chemother; 2011 Jun; 66(6):1301-5. PubMed ID: 21429940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oritavancin Combinations with β-Lactams against Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci.
    Smith JR; Yim J; Raut A; Rybak MJ
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2352-8. PubMed ID: 26833159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determination of antimicrobial susceptibility patterns in Staphylococcus aureus strains recovered from patients at two main health facilities in Kabul, Afghanistan.
    Naimi HM; Rasekh H; Noori AZ; Bahaduri MA
    BMC Infect Dis; 2017 Nov; 17(1):737. PubMed ID: 29187146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.